—white paper
Accurate and sensitive mutation detection with Digital PCR dPCR.
Detecting rare mutations is a cornerstone of cancer and disease research, essential for applications ranging from biomarker to minimal residual disease research studies.
Rare mutation detection involves identifying sequence variants present at very low frequencies (down to 0.1%) in a pool of wild-type background.
The challenge in rare mutation detection is discriminating between two highly similar sequences, where one is significantly more abundant than the other.
This challenge is compounded when working with sample types like FFPE tissue and liquid biopsies where nucleic acids are often fragmented and present at very low levels.
For detecting and quantifying rare events, such as point mutations or single nucleotide polymorphisms (SNPs), you need a sensitive, accurate and precise method.
Digital PCR (dPCR) provides the absolute quantification and reproducibility required for confident rare mutation analysis.
Why use nanoplate dPCR for rare mutation detection?
Ability to load a larger input reaction volume into 26,000 partitions, which substantially increases the chances of finding a rare target
Multiplexing for mutant and wild-type sequencing to detect low fractions of rare mutant molecules against an abundant wild-type background
No need for a standard curve
Rare mutation analysis with nanoplate dPCR
Precise cancer biomarker detection
Looking for reliable, ready-to-use dPCR assays for key oncology targets for your biomarker research?
Digital PCR (dPCR) detection of KRAS G 12C and other variants using IDNAPTEX Assays on QlAcuity
Harness the high sensitivity of the QIAcuity dPCR platform together with new IDNAPTEX multiplex assays.
Confidently detect low-frequency mutations with unmatched sensitivity and speed.
Highly sensitive digital PCR (dPCR) assays, specifically droplet digital PCR (ddPCR), are rapidly becoming the preferred method for detecting KRAS G12C and other codon 12/13 mutations due to their superior sensitivity, often detecting mutant allele frequencies (VAF) below 0.1%. These assays are highly effective in liquid biopsies (ctDNA) and FFPE tissue, providing essential, fast results (<4-6 hours) for therapeutic decisions in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
